MTDA
Pharmaceutical compound
From Wikipedia, the free encyclopedia
MTDA, or MPDA, also known as 3-methoxy-4,5-trimethylenedioxyamphetamine or as 5-methoxy-TDA, is a chemical compound of the phenethylamine and amphetamine families related to the MDxx compounds like MDMA and the EDxx compounds like EDMA.[1][2][3] It is the 5-methoxy derivative of 3,4-trimethylenedioxyamphetamine (TDA) and the analogue of MMDA (5-methoxy-MDA) and MEDA (5-methoxy-EDA) in which the 3,4-alkylenedioxy ring is a further-expanded 3,4-trimethylenedioxy ring.[1][2][3] It was synthesized, tested, and described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[1][2][3] He tested it at doses of up to 8 mg orally and observed no activity.[1][2][3] He did not expect any activity and did not test higher doses before abandoning it, due to it being "not an interesting compound".[1][2][3] MTDA was first described in the scientific literature by Shulgin by 1964.[4][5]
- None
| |
| Clinical data | |
|---|---|
| Other names | MPDA; 3-Methoxy-4,5-trimethylenedioxyamphetamine; 5-Methoxy-3,4-trimethylenedioxyamphetamine; 5-Methoxy-TDA; 5-MeO-TDA |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C13H19NO3 |
| Molar mass | 237.299 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
- Substituted phenethylamine
- Substituted ethylenedioxyphenethylamine
- MEDA (5-methoxy-EDA)
